134 related articles for article (PubMed ID: 38925918)
1. Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections.
Fornari C; Arrieta A; Bradley JS; Tout M; Magalhaes P; Auriol FK; Borella E; Piana C; Pasqua OD; Vallespir BP; Mazzei P; Bokesch PM; Hoover R; Capriati A; Habboubi N
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38925918
[TBL] [Abstract][Full Text] [Related]
2. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation.
Zhuang L; Yu Y; Wei X; Florian J; Jang SH; Reynolds KS; Wang Y
J Clin Pharmacol; 2020 Aug; 60(8):1011-1021. PubMed ID: 32149406
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients.
Trang M; Griffith DC; Bhavnani SM; Loutit JS; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0260620. PubMed ID: 34097490
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
Hanretty AM; Kaur I; Evangelista AT; Moore WS; Enache A; Chopra A; Cies JJ
Pharmacotherapy; 2018 Dec; 38(12):e87-e91. PubMed ID: 30300440
[TBL] [Abstract][Full Text] [Related]
9. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Shoulders BR; Casapao AM; Venugopalan V
Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
[TBL] [Abstract][Full Text] [Related]
10. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Rubino CM; Bhavnani SM; Loutit JS; Morgan EE; White D; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437614
[TBL] [Abstract][Full Text] [Related]
12. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
15. Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data.
Zyryanov S; Bondareva I; Butranova O; Kazanova A
Front Pharmacol; 2023; 14():1079680. PubMed ID: 37007022
[No Abstract] [Full Text] [Related]
16. Optimizing Meropenem Therapy for Severe Nosocomial Infections in Neonates.
Lima-Rogel V; Olguín-Mexquitic L; Kühn-Córdova I; Correa-López T; Romano-Aguilar M; Romero-Méndez MDC; Medellín-Garibay SE; Romano-Moreno S
J Pharm Sci; 2021 Oct; 110(10):3520-3526. PubMed ID: 34089712
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
20. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
